Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label trial of MSB0010718C in metastatic Merkel cell carcinoma after chemotherapy failure
2014-000445-79Phase 2Completed
- Sponsor
- Merck KGaA
- Start
- Sep 2014
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of avelumab in Merkel cell carcinoma (MCC), sponsored by Merck KGaA. Primary endpoint: Objective response rate (ORR). Started Sep 2014; status: completed.
02
Drugs
avelumab
03
Conditions
Merkel cell carcinoma (MCC)
Beyond the preview
Go deeper on 2014-000445-79.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000445-79.